GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (OTCPK:IDXG) » Definitions » Shiller PE Ratio
中文

Interpace Biosciences (Interpace Biosciences) Shiller PE Ratio

: (As of Today)
View and export this data going back to 1998. Start your Free Trial

Shiller PE for Stocks: The True Measure of Stock Valuation


Interpace Biosciences Shiller PE Ratio Historical Data

The historical data trend for Interpace Biosciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Interpace Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Interpace Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Diagnostics & Research subindustry, Interpace Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Interpace Biosciences Shiller PE Ratio Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Interpace Biosciences's Shiller PE Ratio falls into.



Interpace Biosciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Interpace Biosciences's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Interpace Biosciences's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.2/129.4194*129.4194
=0.200

Current CPI (Dec. 2023) = 129.4194.

Interpace Biosciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -11.000 99.695 -14.280
201406 -18.000 100.560 -23.166
201409 -29.000 100.428 -37.372
201412 -50.000 99.070 -65.317
201503 -26.000 99.621 -33.777
201506 -46.000 100.684 -59.129
201509 -31.000 100.392 -39.964
201512 29.600 99.792 38.388
201603 -26.900 100.470 -34.651
201606 -12.900 101.688 -16.418
201609 -41.300 101.861 -52.474
201612 32.400 101.863 41.165
201703 5.500 102.862 6.920
201706 -6.500 103.349 -8.140
201709 -1.500 104.136 -1.864
201712 -1.900 104.011 -2.364
201803 -1.100 105.290 -1.352
201806 -0.700 106.317 -0.852
201809 -1.100 106.507 -1.337
201812 -1.400 105.998 -1.709
201903 -0.940 107.251 -1.134
201906 -1.390 108.070 -1.665
201909 -1.970 108.329 -2.354
201912 -2.890 108.420 -3.450
202003 -2.380 108.902 -2.828
202006 -1.380 108.767 -1.642
202009 -1.540 109.815 -1.815
202012 -2.010 109.897 -2.367
202103 -1.030 111.754 -1.193
202106 -0.840 114.631 -0.948
202109 -0.850 115.734 -0.951
202112 -0.890 117.630 -0.979
202203 -0.530 121.301 -0.565
202206 -0.930 125.017 -0.963
202209 -3.350 125.227 -3.462
202212 -0.370 125.222 -0.382
202303 0.080 127.348 0.081
202306 0.040 128.729 0.040
202309 0.000 129.860 0.000
202312 0.200 129.419 0.200

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Interpace Biosciences  (OTCPK:IDXG) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Interpace Biosciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Interpace Biosciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Interpace Biosciences (Interpace Biosciences) Business Description

Traded in Other Exchanges
Address
300 Interpace Parkway, Morris Corporate Center 1, Building C, Parsippany, NJ, USA, 07054
Interpace Biosciences Inc is engaged in the life sciences industry. It provides molecular diagnostics, bioinformatics, and pathology services for the evaluation of the risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first-line assays principally focused on the early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology. It operates under one segment which is the business of developing and selling diagnostic clinical services.
Executives
Christopher Mccarthy officer: Principal Financial Officer C/O INTERPACE BIOSCIENCES, INC., 300 INTERPACE PARKWAY; BLDG C, 1ST FLOOR, PARSIPPANY NJ 07054
Vijay Aggarwal director 2320 SCIENTIFIC PARK DRIVE, WILMINGTON NC 28405
Thomas W. Burnell director, officer: President and CEO 1355 PEACHTREE STREET, SUITE 1150, ATLANTA GA 30309
Peter H Kamin 10 percent owner 2720 DONALD ROSS ROAD, #311, PALM BEACH GARDENS FL 33410
Fred S. Knechtel officer: Chief Financial Officer REMY INTERNATIONAL, INC., 600 CORPORATION DR., PENDLETON IN 46064
Fortunato R. Rocca director C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE, VISTA CA 92081
Edward Chan director C/O 1315 CAPITAL II, L.P., 2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
1315 Capital Ii, L.p. 10 percent owner 2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
Robert J. Gorman director C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Laurence Mccarthy director 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Ampersand 2018 Limited Partnership 10 percent owner 55 WILLIAM STREET, SUITE 240, WELLESLEY MA 02481
Eric B. Lev director, 10 percent owner C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Thomas John Freeburg officer: Chief Accounting Officer INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PKWY, BLDG. C, PARSIPPANY NJ 07054
Gregory Richard officer: Chief Commerical Officer C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054
Felice Schnoll-sussman director C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054

Interpace Biosciences (Interpace Biosciences) Headlines

From GuruFocus